XML 13 R2.htm IDEA: XBRL DOCUMENT v3.25.1
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 29, 2025
Mar. 30, 2024
Total revenue $ 984,168 $ 1,011,560
Costs and expenses    
Selling, general and administrative 177,799 186,291
Amortization of intangible assets 65,264 32,575
Operating income 74,669 125,977
Other income (expense)    
Interest income 1,404 2,202
Interest expense (27,884) (35,001)
Other income (expense), net (12,211) 5,833
Income before income taxes 35,978 99,011
Provision for income taxes 10,100 24,529
Net income 25,878 74,482
Less: Net income attributable to noncontrolling interests 409 1,522
Net income attributable to Charles River Laboratories International, Inc. 25,469 72,960
Calculation of net income per share attributable to Charles River Laboratories International, Inc. common shareholders    
Net income attributable to Charles River Laboratories International, Inc. 25,469 72,960
Less: Adjustment of redeemable noncontrolling interests 0 401
Less: Incremental dividends attributed to noncontrolling interest holders 0 5,230
Net income available to Charles River Laboratories International, Inc. common shareholders $ 25,469 $ 67,329
Earnings per common share    
Basic (in dollars per share) $ 0.50 $ 1.31
Diluted (in dollars per share) $ 0.50 $ 1.30
Weighted-average number of common shares outstanding    
Basic (in shares) 50,677 51,437
Diluted (in shares) 50,853 51,842
Service    
Total revenue $ 797,923 $ 816,862
Costs and expenses    
Cost of revenue (excluding amortization of intangible assets) 577,428 578,164
Product    
Total revenue 186,245 194,698
Costs and expenses    
Cost of revenue (excluding amortization of intangible assets) $ 89,008 $ 88,553